MOORESTOWN, N.J. , March 10, 2017 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a disruptive innovation and technology leader in medication safety, offering a unique Medication Risk Stratification and Medication Risk Mitigation Matrix® suite of decision support tools, elected Dennis K. Helling, PharmD, ScD (Hon), FCCP, FASHP, FAPhA, to its Board of Directors at the firm’s meeting held March 8, 2017.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/60485f75-51b8-492c-9ef8-7284084e69b6
|
|||||
Dr. Helling is the Executive Director Emeritus, Pharmacy Operations & Therapeutics, Kaiser Permanente Colorado, and Clinical Professor, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Helling served Kaiser from 1992 – 2013.
“TRHC is delighted to welcome Dr. Helling to the Board of Directors,” said Calvin H. Knowlton, PhD, TRHC Chairman and CEO. “He brings to our company outstanding credentials, experience, innovation and leadership in the pharmacy industry generally, and the emerging role of pharmacists in healthcare and personalized medication therapy management, specifically. He joins our company as we emerge as a leader in medication safety. We appreciate Dr. Helling’s willingness to serve as a director and look forward to benefitting from his judgment and counsel.”
Dr. Helling was a Founding Member and President of the American College of Clinical Pharmacy. He also served as President of the Accreditation Council for Pharmacy Education and the American Pharmacists Association Foundation. Currently, he is the Vice President of The Denver Hospice Board of Directors and Chairman of the Working Group on Pharmacy Reimbursement in the Federation of International Pharmacy.
Dr. Helling’s practice emphasis and research have been focused on documenting the impact pharmacists have on improving patient and economic outcomes. A frequent lecturer nationally and internationally, Dr. Helling was the 2013 American Pharmacist Association’s Remington Honor Medalist, the profession’s highest recognition. A graduate of the St. Louis College of Pharmacy (BS Pharm), University of Cincinnati College of Pharmacy (PharmD), Dr. Helling completed a clinical/hospital pharmacy Residency at Cincinnati General Hospital. He also completed the Kaiser Permanente Executive Program, Stanford University School of Business.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to personalize and optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. For more information, please visit: www.trhc.com.
Contact: Media Dianne Semingson [email protected] T: 215-870-0829 Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected]


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Instagram Outage Disrupts Thousands of U.S. Users
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Washington Post Publisher Will Lewis Steps Down After Layoffs
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



